Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced on May 6, 2026, that its compensation committee granted an inducement stock option to Daniel Keefe, the company's recently-hired Commercial Director for the Western U.S. The option, covering 17,000 shares of common stock, was granted on May 5, 2026, as a material inducement for Keefe to join the company, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has an exercise price of $3.20 per share, equal to the closing price on the grant date. One-fourth of the shares vest on the one-year anniversary of the vesting commencement date, with the remainder vesting in equal monthly installments over the next three years, contingent on Keefe's continued service. The option carries a 10-year term and is governed by an inducement stock option agreement.
Aclarion focuses on leveraging biomarkers and proprietary augmented intelligence algorithms through its Nociscan platform to help physicians identify the location of chronic low back pain. The company reported that Nociscan utilization has experienced triple-digit growth, driving the expansion of its commercial team. Keefe's appointment in the Western U.S. is part of this expansion, reflecting increasing demand for the platform.
Nociscan is a cloud-based SaaS platform that receives magnetic resonance spectroscopy data from MRI machines to noninvasively distinguish between painful and nonpainful lumbar discs. By extracting and quantifying chemical biomarkers associated with disc pain, the system provides critical insights to optimize treatment strategies. The company emphasizes that Nociscan is the first evidence-supported platform of its kind.
The inducement grant aligns with Aclarion's strategy to strengthen its commercial presence in key markets. As the company continues to scale, it aims to address the chronic low back pain market, which affects millions of patients. The forward-looking statements in the release note that actual results may differ due to various risks, as detailed in Aclarion's filings with the Securities and Exchange Commission.
For more information about Aclarion and Nociscan, visit www.aclarion.com. The latest news and updates relating to $ACON are available in the company's newsroom at https://tinyurl.com/aconnewsroom.
